Australia's most trusted
source of pharma news
Monday, 20 May 2024
Posted 6 May 2024 AM
The PBAC has four new listings to consider on its May intra-cycle agenda, although only one of them is a new therapeutic.
AbbVie's Vyalev is seeking funding for the treatment of advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy. It just received approval from the TGA after a mammoth wait of almost two-and-a-half years.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.